BR112022019632A2 - Marcadores peptídicos e parceiros de ligação - Google Patents

Marcadores peptídicos e parceiros de ligação

Info

Publication number
BR112022019632A2
BR112022019632A2 BR112022019632A BR112022019632A BR112022019632A2 BR 112022019632 A2 BR112022019632 A2 BR 112022019632A2 BR 112022019632 A BR112022019632 A BR 112022019632A BR 112022019632 A BR112022019632 A BR 112022019632A BR 112022019632 A2 BR112022019632 A2 BR 112022019632A2
Authority
BR
Brazil
Prior art keywords
binding partners
peptide
peptide markers
peptide tags
pairs
Prior art date
Application number
BR112022019632A
Other languages
English (en)
Inventor
Frederik Sander Bertelsen Adam
Elyette Fougeroux Cyrielle
Susan Thrane
Original Assignee
Adaptvac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptvac Aps filed Critical Adaptvac Aps
Publication of BR112022019632A2 publication Critical patent/BR112022019632A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

marcadores peptídicos e parceiros de ligação. a presente invenção diz respeito a marcadores peptídicos e a parceiros de ligação que são capazes de interagir através da formação espontânea de uma ligação isopeptídica, bem como a pares de peptídeos associados e métodos para projetar marcadores peptídicos, parceiros de ligação e pares de peptídeos com propriedades aprimoradas.
BR112022019632A 2020-05-07 2021-05-07 Marcadores peptídicos e parceiros de ligação BR112022019632A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
BR112022019632A2 true BR112022019632A2 (pt) 2023-10-03

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019632A BR112022019632A2 (pt) 2020-05-07 2021-05-07 Marcadores peptídicos e parceiros de ligação

Country Status (11)

Country Link
US (1) US20230321260A1 (pt)
EP (1) EP4146675A1 (pt)
JP (1) JP2023525752A (pt)
KR (1) KR20230006473A (pt)
CN (1) CN115698045A (pt)
AU (1) AU2021268757A1 (pt)
BR (1) BR112022019632A2 (pt)
CA (1) CA3177709A1 (pt)
IL (1) IL297111A (pt)
MX (1) MX2022013938A (pt)
WO (1) WO2021224451A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3244915A1 (en) 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
EP4333864A1 (en) 2021-05-04 2024-03-13 Spybiotech Limited Adenoviral vectors and vaccines thereof
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
EP3244915A1 (en) 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis

Also Published As

Publication number Publication date
US20230321260A1 (en) 2023-10-12
CA3177709A1 (en) 2021-11-11
CN115698045A (zh) 2023-02-03
JP2023525752A (ja) 2023-06-19
MX2022013938A (es) 2022-11-30
AU2021268757A1 (en) 2022-12-08
IL297111A (en) 2022-12-01
WO2021224451A9 (en) 2022-05-27
KR20230006473A (ko) 2023-01-10
WO2021224451A1 (en) 2021-11-11
EP4146675A1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
BR112022019632A2 (pt) Marcadores peptídicos e parceiros de ligação
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
MX2020004149A (es) Variantes de desoxirribonucleasa (dnasa).
BR112022006977A2 (pt) Aminas bicíclicas como inibidores de cdk2
CL2019001660A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.
BR112018005928A2 (pt) composição ácida compreendendo uma ficocianina
BR112018010118A2 (pt) inibidores de cxcr2
BR112018008904A2 (pt) anticorpos que se ligam especificamente a tim-3 e seus usos
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
BR112013003388A2 (pt) sal de besilato de um inibidor de btk
BR112017019453A2 (pt) compostos e composições de alfa-cinamida como inibidores de hdac8
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
CO2018006667A2 (es) Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f
BR112014027303A2 (pt) identificação de variantes de isopreno sintase com propriedades optimizadas para a produção de isopreno
CL2018003655A1 (es) Procedimiento de fabricación de briquetas que contienen un compuesto calcio-magnesiano y un compuesto a base de hierro, y briquetas así obtenidas.
CY1123677T1 (el) Απομονωση αυθεντικων παγκρεατικων προγονικων κυτταρων
BR112022005995A2 (pt) Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente
BR112015026561A2 (pt) artigo compósito e método de fabricação de um artigo compósito
EA201591421A1 (ru) Препараты полипептида фактора ix
BR112019010139A2 (pt) polipeptídeos biespecíficos para gitr e ctla-4
CO2023015915A2 (es) Anticuerpos anti-ccr8